Previous Article | Next Article ![]()
Journal of Virology, November 1998, p. 9348-9352, Vol. 72, No. 11
Department of Gastroenterology and Clinical
Nutrition,
Received 4 May 1998/Accepted 24 July 1998
Studies with human neonatal rotaviruses RV-3 and S12/85 and their
reassortants showed that VP4 is a determinant of rotavirus attachment
to and growth in Caco-2 cells. The binding of these viruses to MA104
and Caco-2 cells correlated with their growth ability. Virus
sensitivity to trypsin and the VP4 fusion region may be implicated in
these processes.
Rotaviruses are triple-layered,
icosahedral particles containing a segmented double-stranded RNA
genome. Both the outer capsid proteins VP4 and VP7 elicit neutralizing,
protective antibodies, define independently segregating serotype
specificities (18), and are implicated in virus cell entry,
although the role of VP7 may be minor (14, 31). The spike
protein VP4 is important in determination of host cell tropism
(19, 25), virulence (21, 24, 36), and viral
attachment and penetration (6, 20, 22, 31). VP4 is a
hemagglutinin in some animal strains (25, 33) and contains a
putative fusion region (34), and its cleavage by trypsin
into subunits VP5* and VP8* (12, 17, 19) enhances virus
infectivity by permitting virus penetration (2, 17, 19)
rather than by increasing virus binding (26).
Rotaviruses infect the mature epithelial cells lining the villi of the
small intestine. Infection can be asymptomatic or cause symptoms
varying from loose stools to copious watery life-threatening diarrhea.
Symptoms of rotavirus infection reflect the balance between host
resistance factors and viral virulence. Virulence has been associated
with genes coding for structural proteins VP3 (24), VP4
(7, 21, 24, 36), and VP7 (24) and nonstructural proteins NSP1 (9), NSP2 (9, 24), and NSP4
(3, 24). The existence of bovine (brv P7[5], G6) and
porcine (prv 4F, prv 4S) rotavirus strains of varying virulence has
been clearly demonstrated in animal models (7, 8) and has
been linked to differences in the ability to replicate in vivo and/or
in vitro (7, 23, 39).
Two human rotavirus strains, RV-3 and S12/85, of identical P2A[6],G3
serotype and subgroup II specificity have been identified in newborn
babies in Melbourne, Australia, as causes of asymptomatic nosocomial
infection in a neonatal nursery (RV-3) or severe community-acquired diarrhea after discharge from hospital (S12/85). RV-3 was isolated from
a stool specimen containing rotavirus of the R electropherotype obtained in 1977 (1, 38), and S12/85 was isolated from a stool specimen obtained in 1985 (28). These strains have
very similar amino acid sequences in genes coding for VP4, VP7, and NSP4 and have identical VP6 sequences (28). However,
conserved amino acid differences between these two strains were
identified at, or near, sites on VP4 that are implicated in
antigenicity, recognition of We now report the growth characteristics of these and other human
rotaviruses in vitro. The abilities of these viruses and their
reassortants, bearing mixtures of genes from RV-3 and S12/85, to bind
and grow in an African green monkey kidney epithelial cell line (MA104)
and in a human colonic adenocarcinoma cell line showing characteristics
typical of small intestinal epithelial cells (Caco-2
[40]) were studied in order to identify the human rotavirus cell attachment protein and specific amino acids that may
influence this process.
Rotavirus S12/85 was adapted to growth in MA104 cells as described
previously (1). Human rotavirus strains previously isolated from asymptomatic neonates were NnB1, a P2A[6],G3 serotype and subgroup II strain of S electropherotype (38) obtained from a stool specimen collected in 1978 (1), M37 (P2A[6],G1),
1076 (P2A[6],G2), and RV-3. An escape mutant of RV-3, vRV-3:3, with a
single amino acid mutation at position 383 (Asn-Lys), which we had
derived by selection with the neutralizing monoclonal antibody (MAb)
RV-3:3 directed to VP4 (13, 27), was also studied.
Reassortants of RV-3 and S12/85 were derived by coinfection of MA104
cells at a multiplicity of infection (MOI) of 1 fluorescent cell-forming unit (FCFU) as described previously (29).
Selection was carried out with antirotavirus MAbs RV3:3 (to neutralize
viruses with VP4 derived from RV-3 [13, 27]) and
A10/N3 (to neutralize viruses with VP7 derived from S12/85 [16,
30]). MAb RV-3:3 neutralized RV-3 and S12/85 to reciprocal
titers of 820,000 and 4,000, respectively. MAb A10/N3 neutralized RV-3
and S12/85 to reciprocal titers of <100 and 1,300, respectively. The
parental origin of each gene segment of all reassortants was determined by electrophoresis in 7.5, 10, and 15% polyacrylamide gels (data not
shown). The origin of VP4 and VP7 was confirmed by sequence analysis of
amino acids (aa) 235 to 242 of VP7 and aa 330 to 380 of VP4, which was
performed as described previously (28). The origin of VP4
and VP7 also was determined by the virus neutralization titer measured
by fluorescent-focus reduction neutralization assay (13)
with MAbs RV-3:3 and A10/N3, the VP4-specific MAb HS11 (37),
and rabbit hyperimmune antisera raised to RV-3 and S12/85 (data not
shown). MAb HS11 neutralized S12/85 to low titer but did not neutralize
RV-3 (data not shown). As shown in Table
1, all reassortants contained single or
multiple segments from S12/85 in the genetic background of RV-3. These
reassortants also all contained gene segment 9 of RV-3, which we have
shown by Northern blot hybridization of a digoxigenin-labelled RV-3 VP7
probe to encode VP7 (data not shown). We were unable to generate
reassortants containing gene 4 of RV-3 in the genetic background of
S12/85, probably because we had no MAb suitable for selection against VP7 of RV-3.
All viruses were propagated in MA104 and Caco-2 cells after activation
with 10 µg of porcine trypsin (Sigma) per ml, followed by
incorporation of 1 µg of trypsin per ml in the maintenance medium
(15). Prior to infection, Caco-2 cells were incubated overnight in medium without fetal calf serum. All viruses grew to
titers of 4 × 105 to 1 × 106 when
inoculated at a MOI of 2 in MA104 cells. As shown in Table 1, Caco-2
cells infected with S12/85, M37, 1076, or NnB1 (MOI, 2) produced a
moderate titer of infectious virus (105 to 106
FCFU/ml) in each of the three to six passages tested. Conversely, RV-3
and vRV-3:3 at the same MOI were unable to establish productive infection in Caco-2 cells. Low levels of virus were detected in the
first two passages only, which may have been due to the virus binding
without penetration of the cell or penetration occurring by a
nonproductive pathway. It was not possible to achieve higher MOI with
RV-3 or vRV-3:3. All reassortants that contained gene segment 4 (encoding VP4) of S12/85 were able to infect and adapt to Caco-2 cells.
The two reassortants unable to infect and adapt to Caco-2 cells (r34
and r214.2) contained gene segment 4 of RV-3.
To determine whether the inability of RV-3 to adapt to growth in Caco-2
cells was due to lack of suitable receptors, the binding of infectious
rotaviruses to cells was measured essentially as described previously
(31), by using 10 µg of trypsin per ml to activate virus,
a MOI of 1 to 3, and an infectivity assay developed previously
(13). The extent of rotavirus binding to Caco-2 cells varied
among the viruses tested (Table 1). Viruses S12/85, NnB1, M37, and
1076, which were able to infect and adapt to growth in Caco-2 cells,
showed high levels of binding (13.3, 16.8, 11, and 13.8%,
respectively). Reassortants that were able to infect and adapt to
Caco-2 cells also exhibited high levels of attachment ranging from 11.5 to 17.1%. In contrast, viruses which contained gene 4 of RV-3 and were
unable to adapt to growth in Caco-2 cells (RV-3, r34, and r214.2)
showed low binding levels (4.8, 4.6, and 2.7%, respectively). The MOI
did not influence the level of binding of RV-3 to Caco-2 cells, since
4.8% of virus bound at a MOI of 1 and 4.9% bound at a MOI of 10. Variant vRV-3:3, which also was unable to adapt to growth in Caco-2
cells, also showed a low level of binding (3.6%). Thus, aa 383 of RV-3
VP4 is not involved in the inability of RV-3 to bind to and grow in
Caco-2 cells.
As shown in Fig. 1, for the 11 serotype
P2A[6] viruses tested, there was a highly statistically significant
correlation at the 95% confidence level between the amount of
infectious virus able to bind to Caco-2 cells and the titer of virus
produced after one passage in these cells (r2 = 0.93; P < 0.0001). The four virus strains with no more
than a single amino acid change from the RV-3 VP4 sequence and a VP7 sequence identical to that of RV-3 (RV-3, vRV-3, r34, and r214.2) showed significantly lower levels of binding and replication than did
the remaining seven strains, which had at least three amino acid
differences in VP4 from RV-3, and were of identical or different G
serotype (unpaired, two-tailed t test, 95% confidence
interval, 0.025
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Attachment and Growth of Human Rotaviruses RV-3
and S12/85 in Caco-2 Cells Depend on VP4

![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
2
1 integrin (14), and
cell fusion and at an antigenic site on VP7 that is possibly involved
in recognition of
4
1 integrin (14) and that is subject
to changes in glycosylation. Any, or all, of these changes have the
potential to influence viral growth in vivo and in vitro.
TABLE 1.
Attachment and growth of neonatal, reassortant, and
variant rotaviruses in Caco-2 cellsa
P
0.047 for binding and
0.0025
P
0.048 for virus replication).

View larger version (18K):
[in a new window]
FIG. 1.
Correlation of binding of infectious, MA104
cell-adapted, serotype P2A[6] rotaviruses to Caco-2 cells with the
titer of virus produced after a single passage in these cells. Viruses
with similar binding and growth characteristics as determined by
statistical analysis were grouped as described in the text. A, viruses
with VP4 derived from RV-3 (RV-3, r34, and r214.2) or with a single
mutation of the RV-3 VP4 amino acid sequence (vRV-3:3); B, viruses with
VP4 sequences showing at least three amino acid differences from the
sequence of RV-3 (S12/85, r6, r26, r31, NnB1, M37, and 1076).
These results show that the ability of a range of cultivable serotype P2A rotaviruses to infect MA104 and Caco-2 cells correlated with the ability of at least 11% of infectious virus present to bind to the cells, and VP4 was critical for S12/85 to bind and infect Caco-2 cells. VP7 did not appear to influence Caco-2 binding and replication. In previous studies, Bass et al. (5) showed that radiolabelled rotaviruses bound to similar extents to both permissive (MA104) and nonpermissive (mouse L) cells, as measured by virus escape from cell surface protease treatment. This difference from our findings may be due to the different viruses, cell lines, and virus detection methods employed. Our results suggest either that RV-3 cannot identify a necessary receptor on Caco-2 cells or that the level or affinity of binding to this receptor is too low for productive infection. This may be because the binding sites necessary on the VP4 protein are altered compared with strain S12/85. It is also possible that RV-3 does not efficiently penetrate or uncoat in Caco-2 cells. However, it is unlikely that the inability of RV-3 and vRV-3:3 to grow in Caco-2 cells was due to a postentry block in virus replication. Firstly, the monoreassortants, containing a single gene from S12/85 and the remaining 10 gene segments from RV-3, grew to a titer indistinguishable from that of S12/85 itself, suggesting that RV-3 would replicate adequately in Caco-2 cells if the binding and entry steps are bypassed. Secondly, it is very unlikely that gene 4, encoding the cell attachment protein VP4, which is also required for entry, would also on its own control any later growth restriction. Thirdly, both of the two rotaviruses (rhesus rotavirus RRV and bovine rotavirus UK) tested previously (5) were able to replicate in both permissive (MA104 and HT29) and nonpermissive (L and HEp 2) cell lines after lipofection of noninfectious, double-layered virus particles.
In contrast to their binding to Caco-2 cells, RV-3 and S12/85 showed similar abilities to bind to MA104 cells, with 15.7% of input infectious RV3 virus and 13.7% of input infectious S12/85 virus binding to MA104 cells (P = 0.52). Hence, the cell receptors utilized by these viruses may vary with cell line, as was found for murine rotavirus EHP. The infectivity of EHP in Caco-2 cells was dependent on the presence of sialic acid on the cell surface but was independent of sialic acid in MA104 cells (31).
The VP4 proteins of fecally derived RV-3 and S12/85 rotaviruses showed 99.1% amino acid identity (28). Upon adaption to growth in MA104 cells, both RV-3 and S12/85 sustained mutations in VP4. The changes in RV-3 were at aa 439 (Leu to Ser) and at aa 466 (Arg to Gly). In S12/85, aa 388 (Ile to Leu) and aa 479 (Tyr to His) were altered (Table 2). Sequence comparisons of the entire VP4 of MA104 cell-adapted S12/85 and NnB1 viruses with RV-3 revealed three conserved amino acid differences at aa 30 (Asp to Ser), 241 (Ser to Ala), and 388 (Leu to Ile). Similar comparisons with M37 and 1076 rotaviruses showed conservation of Ser at aa 241 and either Leu (M37) or Met (1076) at aa 388, whereas Ser was present at aa 30 in 1076.
|
Thus, conserved differences in sequence at a site of trypsin cleavage (aa 241) and in the putative fusion region at aa 388 (34) were consistent with differences in the ability of neonatal rotaviruses to replicate in Caco-2 cells. It is possible that differences in VP7 sequence between some of these viruses contribute to this replication property in some cases. Differences at these positions in VP4 do not correspond to those at aa 133, 303, and 380 in P2A[6],G3 rotaviruses, including stool RV-3 and S12/85, which were implicated in viral virulence in our earlier study (28). Thus, results from in vitro cell culture studies may not necessarily provide information to help explain differences in virulence between rotavirus strains.
The efficiency of virus attachment after activation at different
trypsin levels was studied for RV-3 and S12/85 in MA104 and Caco-2
cells. Stocks of RV-3 and S12/85 with uncleaved VP4 were produced by
inoculation of MA104 cells with trypsin-activated virus for 1 h.
The inoculum was removed, and monolayers were washed twice with
phosphate-buffered saline before Dulbecco modified Eagle medium
containing the protease inhibitors leupeptin and pepstatin at 10 mg/ml
and 0.5% (vol/vol) fetal calf serum was added (32). Virus
was harvested at 20 h postinfection. Lack of VP4 cleavage was
confirmed by polyacrylamide gel electrophoresis and Western blotting
with the appropriate hyperimmune antiserum. Virus with uncleaved VP4
was treated with concentrations of trypsin from 0 to 100 µg/ml and
then used in the virus-cell binding assay (Fig.
2). RV-3 and S12/85 with uncleaved VP4
bound to MA104 cells with an efficiency similar to that of virus
treated with 10 to 100 µg of trypsin per ml (t test,
0.10
P
0.36). The level of S12/85 attachment
to Caco-2 cells and to MA104 cells was similar to that of RV-3 to MA104
cells over the range of trypsin levels tested (0.15
P
0.83), and a significantly greater percentage of
S12/85 virus not treated with trypsin bound to Caco-2 cells than that
of S12/85 treated with 50 to 100 µg of trypsin per ml (0.026
P
0.037). Of most interest, levels of binding of
RV-3 to Caco-2 cells were significantly lower than those to MA104 cells at 0 to 50 µg of trypsin per ml (0.012
P
0.05) but not at 100 µg of trypsin per ml (P = 0.059).
|
To determine the effect of trypsin on rotavirus growth, virus stocks
with intact VP4 were activated with a range of trypsin concentrations
at 37°C for 20 min. Confluent monolayers of MA104 cells in 24-well
trays were inoculated with activated virus at a MOI of 1, and virus was
harvested at 20 h postinfection. The titer of rotaviruses produced
was influenced by the trypsin concentration used for virus activation.
The maximum titer of RV-3 was obtained after activation with 10 µg of
trypsin per ml (Fig. 3). At 100 µg of
trypsin per ml, virus yield was reduced to 37.6% of that at 10 µg/ml. In contrast, S12/85 showed maximal virus production after
activation at a trypsin concentration of 20 µg/ml, and at a trypsin
concentration of 100 µg/ml the S12/85 virus titer was only 1% of the
titer at 20 µg/ml. Thus, RV-3 tolerated a much wider range of trypsin
concentrations than S12/85, which was sensitive to high levels of
trypsin. As shown in Fig. 3A, RV-3 titers at 10 to 100 µg of trypsin
per ml were significantly different from all the other rotaviruses
tested, at the 99% level (t test, 0.0006
P
0.008), whereas S12/85 titers were not
significantly different from NnB1 titers (0.01
P
0.83) or 1076 titers (0.018
P
0.31). Thus, like S12/85, NnB1 and 1076 were also
very sensitive to trypsin levels above 10 µg/ml. Reassortants r26 and
r223 showed titers indistinguishable from each other at 10 to 100 µg
trypsin per ml (0.04
P
0.62). The titers of
both reassortants were significantly different from that of RV-3
(0.001
P
0.008) but not from that of S12/85
(0.012
P
0.084) at 10 to 50 µg of trypsin
per ml. At 100 µg of trypsin per ml, the titers of r223
(P = 0.0004) and r26 (P = 0.0018) were
significantly different from that of S12/85 and from that of RV-3
(0.004
P
0.005). This shows that, with the
exception of the highest trypsin level tested, the sensitivities of
r223 and r26 to trypsin are similar to that of S12/85 and that this
sensitivity is a property of S12/85 VP4. These results support previous
findings that cleavage of VP4 with trypsin concentrations up to 25 µg/ml correlated with increasing rotavirus infectivity
(2). The reassortant titers also suggest that genes other
than VP4 may affect trypsin sensitivity. It is likely that VP4-VP7
interactions, previously reported to affect antigenicity
(11), may also affect trypsin sensitivity. Additionally, at
elevated trypsin levels, other viral proteins may be trypsin sensitive.
For example, solubilized VP7 is cleaved by trypsin and induces
permeabilization of cell vesicles (10). We did not see
evidence of VP7 cleavage by Western blot at 10 µg of trypsin per ml
(data not shown).
|
Community viruses P (P1A[8],G3), RV-4 (P1A[8],G1), and RV-5
(P1B[4],G2) grew to high titer in Caco-2 cells (data not shown). In
MA104 cells, all showed an increase in titer with concentrations of
trypsin up to 10 µg/ml (Fig. 3B). Further increases in trypsin concentration to 100 µg/ml produced virus titer reductions of 98.9%
(RV-4), 96.1% (P), and 82.1% (RV-5). P and RV-4 showed significantly lower titers than RV-3 at 20 to 100 µg of trypsin per ml (0.0008
P
0.007), and RV-5 showed significantly lower
titers at 50 µg of trypsin per ml (P = 0.004). Thus,
the trypsin resistance and high titers of RV-3 in MA104 cells are
unusual among human rotaviruses.
Assuming that the VP4 amino acid sequence changes which occurred on adaption of RV-3 and S12/85 to culture, and which were not at or near sites of trypsin cleavage, do not affect the trypsin sensitivity of these viruses, this result may have implications for virus growth in the intestine. Theoretically, it would be advantageous for a virus to be able to replicate over a wide range of trypsin concentrations, particularly in neonates whose intestinal trypsin levels can vary greatly during the first few weeks of life (4, 35). P2A[6],G3 rotaviruses, of which RV-3 and NnB1 are representative, have been shown to be endemic in obstetric hospital nurseries in Melbourne, Australia, without causing disease for at least 10 years (1). Those rotaviruses like RV-3 may be particularly well suited to growth in the neonatal gut.
Nucleotide sequence accession numbers. The sequences of S12/85 and NnB1, determined in this study, have been deposited in GenBank under accession no. AF076925 and AF076926, respectively.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by project grants 940302 and 940315 from the National Health and Medical Research Council of Australia and by the Royal Children's Hospital Research Foundation.
We are grateful to Jon Gentsch and Luis Padilla-Noriega for the HS11 MAb.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Immunology, The University of Melbourne, Royal Parade, Parkville 3052, Victoria, Australia. Phone: 61 3 9344 8823. Fax: 61 3 9347 1540. E-mail: b.coulson{at}microbiology.unimelb.edu.au.
Present address: Viral Gastroenteritis Section, Division of Viral
and Rickettsial Diseases, National Center for Infectious Diseases,
Centers for Disease Control and Prevention, Atlanta, GA 30333.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Albert, M. J.,
L. E. Unicomb,
G. L. Barnes, and R. F. Bishop.
1987.
Cultivation and characterization of rotavirus strains infecting newborn babies in Melbourne, Australia, from 1975 to 1979.
J. Clin. Microbiol.
25:1635-1640 |
| 2. | Arias, C. F., P. Romero, V. Alvarez, and S. Lopez. 1996. Trypsin activation pathway of rotavirus infectivity. J. Virol. 70:5832-5839[Abstract]. |
| 3. | Ball, J. M., P. Tian, C. Q. Zeng, A. P. Morris, and M. K. Estes. 1996. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 272:101-104[Abstract]. |
| 4. | Barnes, G. L. 1991. Intestinal viral infections, p. 538-546. In Pediatric gastrointestinal disease. Marcel Dekker, Inc., New York, N.Y. |
| 5. | Bass, D. M., M. R. Baylor, C. Chen, E. M. Mackow, M. Bremont, and H. B. Greenberg. 1992. Liposome-mediated transfection of intact viral particles reveals that plasma membrane penetration determines permissivity of tissue culture cells to rotavirus. J. Clin. Investig. 90:2313-2320. |
| 6. | Bass, D. M., E. R. Mackow, and H. B. Greenberg. 1991. Identification and partial characterization of a rhesus rotavirus binding glycoprotein on murine enterocytes. Virology 183:602-610[Medline]. |
| 7. |
Bridger, J. C.,
B. Burke,
G. M. Beards, and U. Desselberger.
1992.
The pathogenicity of two porcine rotaviruses differing in their in vitro growth characteristics and genes 4.
J. Gen. Virol.
73:3011-3015 |
| 8. | Bridger, J. C., and D. H. Pocock. 1986. Variation in virulence of bovine rotaviruses. J. Hyg. 96:257-264. |
| 9. |
Broome, R. L.,
P. T. Vo,
R. L. Ward,
H. F. Clark, and H. B. Greenberg.
1993.
Murine rotavirus genes encoding outer capsid proteins VP4 and VP7 are not major determinants of host range restriction and virulence.
J. Virol.
67:2448-2455 |
| 10. | Charpilienne, A., M. J. Abad, F. Michelangeli, F. Alvarado, M. Vasseur, J. Cohen, and M. C. Ruiz. 1997. Solubilized and cleaved VP7, the outer glycoprotein of rotavirus, induces permeabilization of cell membrane vesicles. J. Gen. Virol. 78:1367-1371[Abstract]. |
| 11. |
Chen, D. Y.,
M. K. Estes, and R. F. Ramig.
1992.
Specific interactions between rotavirus outer capsid proteins VP4 and VP7 determine expression of a cross-reactive, neutralizing VP4-specific epitope.
J. Virol.
66:432-439 |
| 12. |
Clark, S. M.,
J. R. Roth,
M. L. Clark,
B. B. Barnett, and R. S. Spendlove.
1981.
Trypsin enhancement of rotavirus infectivity: mechanism of enhancement.
J. Virol.
39:816-822 |
| 13. |
Coulson, B. S.,
K. J. Fowler,
R. F. Bishop, and R. G. Cotton.
1985.
Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates.
J. Virol.
54:14-20 |
| 14. |
Coulson, B. S.,
S. L. Londrigan, and D. J. Lee.
1997.
Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells.
Proc. Natl. Acad. Sci. USA
94:5389-5394 |
| 15. |
Coulson, B. S.,
L. E. Unicomb,
G. A. Pitson, and R. F. Bishop.
1987.
Simple and specific enzyme immunoassay using monoclonal antibodies for serotyping human rotaviruses.
J. Clin. Microbiol.
25:509-515 |
| 16. |
Dyall-Smith, M. L.,
I. Lazdins,
G. W. Tregear, and I. H. Holmes.
1986.
Location of the major antigenic sites involved in rotavirus serotype-specific neutralization.
Proc. Natl. Acad. Sci. USA
83:3465-3468 |
| 17. |
Espejo, R. T.,
S. Lopez, and C. Arias.
1981.
Structural polypeptides of simian rotavirus SA11 and the effect of trypsin.
J. Virol.
37:156-160 |
| 18. | Estes, M. K. 1996. Rotaviruses and their replication, p. 1625-1655. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 19. |
Estes, M. K.,
D. Y. Graham, and B. B. Mason.
1981.
Proteolytic enhancement of rotavirus infectivity: molecular mechanisms.
J. Virol.
39:879-888 |
| 20. | Fukudome, K., O. Yoshie, and T. Konno. 1989. Comparison of human, simian, and bovine rotaviruses for requirement of sialic acid in hemagglutination and cell adsorption. Virology 172:196-205[Medline]. |
| 21. |
Gorziglia, M.,
K. Green,
K. Nishikawa,
K. Taniguchi,
R. Jones,
A. Z. Kapikian, and R. M. Chanock.
1988.
Sequence of the fourth gene of human rotaviruses recovered from asymptomatic or symptomatic infections.
J. Virol.
62:2978-2984 |
| 22. |
Greenberg, H. B.,
J. Flores,
A. R. Kalica,
R. G. Wyatt, and R. Jones.
1983.
Gene coding assignments for growth restriction, neutralization and subgroup specificities of the W and DS-1 strains of human rotavirus.
J. Gen. Virol.
64:313-320 |
| 23. | Hall, G. A., J. C. Bridger, K. R. Parsons, and R. Cook. 1993. Variation in rotavirus virulence: a comparison of pathogenesis in calves between two rotaviruses of different virulence. Vet. Pathol. 30:223-233[Abstract]. |
| 24. | Hoshino, Y., L. J. Saif, S. Y. Kang, M. M. Sereno, W. K. Chen, and A. Z. Kapikian. 1995. Identification of group A rotavirus genes associated with virulence of a porcine rotavirus and host range restriction of a human rotavirus in the gnotobiotic piglet model. Virology 209:274-280[Medline]. |
| 25. | Kalica, A. R., J. Flores, and H. B. Greenberg. 1983. Identification of the rotaviral gene that codes for hemagglutination and protease-enhanced plaque formation. Virology 125:194-205[Medline]. |
| 26. | Keljo, D. J., and A. K. Smith. 1988. Characterization of binding of simian rotavirus SA-11 to cultured epithelial cells. J. Pediatr. Gastroenterol. Nutr. 7:249-256[Medline]. |
| 27. | Kirkwood, C. D., R. F. Bishop, and B. S. Coulson. 1996. Human rotavirus VP4 contains strain-specific, serotype-specific and cross-reactive neutralization sites. Arch Virol. 141:587-600[Medline]. |
| 28. | Kirkwood, C. D., B. S. Coulson, and R. F. Bishop. 1996. G3P2 rotaviruses causing diarrhoeal disease in neonates differ in VP4, VP7 and NSP4 sequence from G3P2 strains causing asymptomatic neonatal infection. Arch. Virol. 141:1661-1676[Medline]. |
| 29. | Kobayashi, N., K. Kojima, K. Taniguchi, T. Urasawa, and S. Urasawa. 1994. Genotypic diversity of reassortants between simian rotavirus SA11 and human rotaviruses having different antigenic specificities and RNA patterns. Res. Virol. 145:303-311[Medline]. |
| 30. |
Lazdins, I.,
S. Sonza,
M. L. Dyall-Smith,
B. S. Coulson, and I. H. Holmes.
1985.
Demonstration of an immunodominant neutralization site by analysis of antigenic variants of SA11 rotavirus.
J. Virol.
56:317-319 |
| 31. | Ludert, J. E., N. Feng, J. H. Yu, R. L. Broome, Y. Hoshino, and H. B. Greenberg. 1996. Genetic mapping indicates that VP4 is the rotavirus cell attachment protein in vitro and in vivo. J. Virol. 70:487-493[Abstract]. |
| 32. |
Ludert, J. E.,
A. A. Krishnaney,
J. W. Burns,
P. T. Vo, and H. B. Greenberg.
1996.
Cleavage of rotavirus VP4 in vivo.
J. Gen. Virol.
77:391-395 |
| 33. |
Mackow, E. R.,
J. W. Barnett,
H. Chan, and H. B. Greenberg.
1989.
The rhesus rotavirus outer capsid protein VP4 functions as a hemagglutinin and is antigenically conserved when expressed by a baculovirus recombinant.
J. Virol.
63:1661-1668 |
| 34. |
Mackow, E. R.,
R. D. Shaw,
S. M. Matsui,
P. T. Vo,
M. N. Dang, and H. B. Greenberg.
1988.
The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region.
Proc. Natl. Acad. Sci. USA
85:645-649 |
| 35. |
McLean, B. S., and I. H. Holmes.
1981.
Effects of antibodies, trypsin, and trypsin inhibitors on susceptibility of neonates to rotavirus infection.
J. Clin. Microbiol.
13:22-29 |
| 36. |
Offit, P. A.,
G. Blavat,
H. B. Greenberg, and H. F. Clark.
1986.
Molecular basis of rotavirus virulence: role of gene segment 4.
J. Virol.
57:46-49 |
| 37. |
Padilla Noriega, L.,
R. Werner Eckert,
E. R. Mackow,
M. Gorziglia,
G. Larralde,
K. Taniguchi, and H. B. Greenberg.
1993.
Serologic analysis of human rotavirus serotypes P1A and P2 by using monoclonal antibodies.
J. Clin. Microbiol.
31:622-628 |
| 38. |
Rodger, S. M.,
R. F. Bishop,
C. Birch,
B. McLean, and I. H. Holmes.
1981.
Molecular epidemiology of human rotaviruses in Melbourne, Australia, from 1973 to 1979, as determined by electrophoresis of genome ribonucleic acid.
J. Clin. Microbiol.
13:272-278 |
| 39. | Tzipori, S., L. Unicomb, R. Bishop, J. Montenaro, and L. M. Vaelioja. 1989. Studies on attenuation of rotavirus. A comparison in piglets between virulent virus and its attenuated derivative. Arch. Virol. 109:197-205[Medline]. |
| 40. | Vachon, P. H., and J. F. Beaulieu. 1992. Transient mosaic patterns of morphological and functional differentiation in the Caco-2 cell line. Gastroenterology 103:414-423[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|